Drug Policy Watch · State Brief 2026

Oregon

Snapshot (structured)

Adult-use cannabis: Legal since 2014 (Measure 91), retail sales began October 2015, regulated by OLCC.
Medical cannabis: Legal since 1998 (Oregon Medical Marijuana Act, Measure 67), administered by OHA.
Home grow: Allowed, up to 4 plants per household for adults 21+.
Intoxicating hemp / hemp THC: Heavily restricted; Oregon bans artificially derived cannabinoids (delta-8, delta-10, HHC, THC-O, THC-P) and regulates hemp-derived THC under OLCC and ODA.
Psychedelics: Regulated adult psilocybin services under Measure 109 (the first such program in the US); not a medical model, no decriminalization of personal possession after the Measure 110 rollback.
Broad decriminalization: Repealed. Measure 110 (2020) decriminalized personal drug possession; HB 4002 (2024) recriminalized it effective September 1, 2024.
Harm reduction: Robust; syringe services, broad naloxone access, legal fentanyl test strips.
Governor (party): Tina Kotek (Democrat).
Legislature control: Democratic trifecta; Democrats hold both chambers.
Citizen ballot initiatives allowed: Yes, Oregon has a strong citizen initiative and referendum process.
Enclosure pressure score: 3/5

Cannabis

Oregon legalized adult-use cannabis through Measure 91 in November 2014, with regulated retail sales beginning in October 2015. Medical cannabis has been legal since 1998 under the Oregon Medical Marijuana Act (Measure 67). Adults 21 and over may grow up to 4 plants per household. The market is regulated by the Oregon Liquor and Cannabis Commission (OLCC).

Market structure is defined by a long-running license moratorium. Oregon's OLCC licensing moratorium was ratified by the legislature in 2024 and, in 2025, extended until at least March 2027; new applications for producer, processor, wholesaler, and retailer licenses are not being accepted, operating under a population-ratio formula that functions as a near-permanent cap with a limited buy/sell ("one in, one out") path for existing licenses (Harris Sliwoski, OLCC licensing and market updates). As of mid-2025 there were over 3,000 active marijuana licensees, with numbers declining marginally and the market in chronic oversupply (median usable marijuana price around $3.33/gram in April 2025) (Harris Sliwoski, State of the State 2025). The state levies a 17% cannabis excise tax on retail sales, with local jurisdictions able to add up to 3%, and no general state sales tax (Cannabis CPA Tax, Oregon guide 2025). MSO presence is comparatively limited because Oregon has long required in-state ownership/residency for licensees, a structure now under legal pressure (see Active legislation and Enclosure read).

Key 2026 actions: the 35-day short session (February 2 to March 6, 2026) was not cannabis-focused. The omnibus cannabis bill HB 4139 collapsed and was sent to Ways and Means without further action; HB 4142 (a medical-marijuana access bill known as "Ryan's Law") passed and was signed by Governor Kotek; SB 1548 (packaging/edible dosing and buffer zones) failed; HB 4162 (a labor-peace repeal effort) was introduced (Harris Sliwoski, 2026 Legislative Forecast; Harris Sliwoski, New Cannabis Laws 2026 Edition).

Hemp

Oregon is among the strictest states on intoxicating hemp. Under HB 3000 (2021) and subsequent rulemaking, the state banned artificially derived cannabinoids, including delta-8, delta-10, HHC, THC-O, and THC-P, with CBN treated separately, and folded hemp-derived THC products into the OLCC-regulated channel (Vaping360, Oregon bans artificially derived cannabinoids; MPP Oregon). HB 3825 (2025) reinforced prohibitions on artificially derived cannabinoids and tightened testing and labeling standards (Substance Cannabis Market, Oregon Cannabis Laws 2026). Beginning January 1, 2026, an industrial-hemp product containing an artificially derived cannabinoid may be approved only if OLCC judges it non-impairing at the intended concentration and the cannabinoid is documented as naturally occurring in at least three peer-reviewed publications (Harris Sliwoski, New Rules).

Federal exposure: the Continuing Appropriations and Extensions Act (H.R. 5371), signed November 12, 2025, replaces the 2018 Farm Bill's delta-9-only standard with a total-THC standard, caps finished products at 0.4 mg total THC per container, and excludes synthetic cannabinoids from the hemp definition. These changes take effect November 12, 2026, and industry groups estimate roughly 95% of existing hemp-derived cannabinoid products would become non-compliant (Vicente LLP, 2026 Federal Hemp Ban; Harris Sliwoski, unsold hemp inventory). Because Oregon already bans most intoxicating hemp cannabinoids, its retail exposure is lower than in permissive states, but Oregon's 2026 omnibus effort (HB 4139) to align state law with the new federal rules and to tax hemp-derived cannabinoid products at 17% stalled when marijuana and hemp stakeholders could not agree (Harris Sliwoski, 2026 Legislative Forecast). A federal one-year delay to November 12, 2027 was proposed (an amendment attributed to Rep. James Comer, R-KY) but as of early 2026 the ban remained in the 2026 Farm Bill markup untouched (Cannabis Business Times).

Psychedelics

Oregon voters approved Measure 109 in 2020, creating the nation's first regulated adult psilocybin services program, administered by Oregon Psilocybin Services (OPS) within the Oregon Health Authority. The program is a supervised-services model (clients consume psilocybin at licensed service centers with trained facilitators); it is not a medical/prescription model and does not depend on a diagnosis. Applications opened January 2, 2023, and service centers began opening in summer 2023 (OHA Oregon Psilocybin Services).

Program status: by 2025 OHA had licensed roughly 30 to 31 service centers, about 356 facilitators, around 12 manufacturers, and one laboratory, with approximately 8,000 clients served (Wikipedia, 2020 Oregon Ballot Measure 109; OregonPsychedelics.org, psilocybin laws 2026). The program faces financial strain: OHA reported tapping about $3.1 million from the general fund to operate the program because licensing-fee revenue has been weak, and service centers have been closing amid high costs and heavy regulation (Willamette Week, June 2025).

2026 rules and bills: for renewals received on or after January 1, 2026, facilitators must complete four hours of continuing education annually, and training programs must be registered with the Oregon Secretary of State (OPS facilitator information). HB 4040, signed by Governor Kotek on April 7, 2026, bundles roughly two dozen health-law changes; its psilocybin provisions allow, beginning January 1, 2027, reciprocity for facilitators trained in other states whose curricula OPS finds meet or exceed Oregon requirements (Colorado already determined to qualify), and add the Occupational Therapy and Physical Therapy boards to dual-licensure provisions created by HB 2387 (2025) (Hoodline on HB 4040; OLIS HB 4040; OregonPsychedelics.org, psilocybin laws 2026). Personal, non-program possession of psilocybin is not decriminalized following the Measure 110 rollback. A 2025 court ruling was reported as moving Oregon closer to legal in-home psilocybin use; the practical effect is unconfirmed and the matter remained unsettled (Reason, June 2025).

Broader drug policy

Measure 110, approved by voters in November 2020 and effective February 2021, decriminalized personal-use possession of all drugs (replacing criminal penalties with a $100 citation dismissible by a health screening) and redirected cannabis tax revenue to treatment and recovery services. Facing rising overdose deaths, public-disorder concerns, and the threat of a tougher rollback initiative on the November 2024 ballot, the legislature passed HB 4002 in the 2024 session, which Governor Kotek signed in early April 2024. HB 4002 created a new "drug enforcement misdemeanor" for simple possession (recriminalizing it), with the criminal portion effective September 1, 2024; it preserved much of Measure 110's treatment funding and built in deflection/treatment off-ramps (up to 18 months probation, with limited jail exposure for violations). Companion funding came through SB 5204 (KGW, Kotek signs rollback; Plural Policy, HB 4002; ACLU of Oregon, HB 4002). Civil-liberties and racial-justice groups opposed the rollback, warning of disproportionate impact on Black and Latino communities (KGW, Capitol protest).

Harm reduction remains strong. Oregon's 2023 Opioid Harm Reduction Package (HB 2395) expanded naloxone access in public buildings and through first responders, granted civil and criminal immunity for naloxone administration, and decriminalized distribution of fentanyl test strips; syringe services programs operate statewide and also distribute naloxone and test strips (Oregon House Democrats, Opioid Harm Reduction Package).

Sentencing and expungement: Senate Bill 420 (2019, effective January 1, 2020) created an expedited, no-fee process to expunge and seal qualifying marijuana convictions, waiving the usual ten-year clean-record requirement and the background-check step; records are sealed rather than destroyed (ACLU of Oregon, SB 420 and SB 975; McKean Smith, SB 420). Relief is petition-based rather than fully automatic. The framing of a broader Oregon Cannabis Equity Act to fund automatic expungement has been discussed; its current legislative status is unconfirmed (Point Seven Group, Oregon expungement guide).

Political landscape

Governor Tina Kotek (Democrat), elected 2022 and seeking reelection in 2026, leads a Democratic trifecta (Wikipedia, Tina Kotek; Yahoo News, Kotek 2026 reelection). After the 2024 elections Democrats held an 18-12 Senate majority and a 35-25 House majority; a September 5, 2025 party switch by Rep. Cyrus Javadi from Republican to Democrat moved the House to a 37-23 Democratic majority for the 2026 short session (Ballotpedia, 2026 Oregon legislative session; Wikipedia, 83rd Oregon Legislative Assembly).

Key committees touching drug policy include the Senate Behavioral Health Committee (whose chair brought SB 1548); the specific chair's name is unconfirmed. House and Senate health and judiciary committees handle psilocybin, harm-reduction, and possession matters. Named reform champions and named opponents for the 2026 cannabis/psychedelic bills are not reliably confirmable from available sources, so they are marked unconfirmed rather than guessed. On the advocacy side, the ACLU of Oregon and the Oregonians for Safety and Recovery coalition publicly opposed the Measure 110 rollback (ACLU of Oregon); the Cannabis Industry Association of Oregon (CIAO) was central to the 2026 hemp/omnibus working group, and UFCW Local 555 has driven the labor-peace (BM 119) fight (Harris Sliwoski, 2026 Legislative Forecast).

Ballot initiatives

Oregon allows citizen-initiated ballot measures (initiatives and referenda) and has used them heavily for drug policy: Measure 67 (1998, medical), Measure 91 (2014, adult-use), Measure 109 (2020, psilocybin), and Measure 110 (2020, decriminalization) were all citizen-driven. The threat of a 2024 citizen initiative to roll back Measure 110 is widely credited with prompting the legislature to act first via HB 4002 (Rogue Valley Times). Ballot Measure 119 (2024) imposed labor-peace agreement requirements on cannabis licensees; a US District Court struck it down (reported May 20, 2025) as unconstitutional, and the case is on appeal, with HB 4162 (2026) representing a legislative effort to repeal it (Harris Sliwoski, 2026 Legislative Forecast). No confirmed new statewide cannabis, psychedelic, or drug-policy citizen measure for the 2026 ballot was identified in available sources; treat as unconfirmed.

Equity and expungement

Marijuana-conviction relief runs through SB 420 (2019), an expedited petition-based expungement and record-sealing pathway with no filing fee and no ten-year clean-record requirement; the district attorney has 30 days to object (ACLU of Oregon, SB 420; McKean Smith). Because relief is petition-based rather than automatic, people who do not file (often the most marginalized) are effectively excluded from benefit; the City of Portland and partners have funded clinics to close that gap (The Skanner). Oregon's adult-use licensing framework does not center a formal social-equity license tier comparable to some states; the OLCC moratorium and residency requirements shape who can enter the market more than an equity-license program does. A broader Oregon Cannabis Equity Act to fund automatic expungement has been discussed but its current status is unconfirmed.

Market and barriers

Cannabis excise tax: 17% state, plus up to 3% local; no general state sales tax (Cannabis CPA Tax).
License caps: de facto cap via population-ratio moratorium; new producer, processor, wholesaler, and retailer applications closed, extended to at least March 2027, with a limited buy/sell transfer path (Harris Sliwoski, OLCC updates).
Approximate licensees: over 3,000 active marijuana licensees as of mid-2025 (Harris Sliwoski, State of the State 2025).
Psilocybin program (2025): roughly 30 to 31 service centers, about 356 facilitators, around 12 manufacturers, one lab; about 8,000 clients served; program running a general-fund deficit (about $3.1 million tapped) (Wikipedia, Measure 109; Willamette Week).
Residency/ownership: Oregon has long required in-state ownership/residency for cannabis licensees; this is being challenged on dormant-commerce-clause grounds (Harris Sliwoski, dormant commerce clause). Specific current license-fee dollar amounts were not confirmed in available sources; check OLCC's marijuana licensing page.

Enclosure read

Oregon presents a mixed picture. Several features keep the door open: low taxes by national standards, generous home-grow rights, a strong citizen-initiative tradition, robust harm reduction, and historic in-state residency rules that have kept large multistate operators (MSOs) from dominating the way they do in limited-license states. That residency wall, however, is under direct legal attack on dormant-commerce-clause grounds, and if it falls, consolidation pressure rises. On the fencing side: the multi-year OLCC license moratorium (now extended to at least March 2027) functions as a near-permanent cap that fences out new entrants and converts licenses into scarce, tradable assets favoring incumbents; chronic oversupply and rock-bottom wholesale prices squeeze small producers regardless of policy. In psilocybin, high compliance costs, weak fee economics, and closing service centers are fencing out small operators and pricing out clients, pushing the first-in-the-nation program toward a smaller set of better-capitalized survivors. On the consumer/criminal-legal side, the HB 4002 recriminalization re-fenced personal possession after a brief decriminalization window, with disproportionate-impact concerns. Net: real openness on home grow, taxes, and direct democracy, offset by structural enclosure in licensing and a recriminalized possession regime. Score: 3/5.

What to watch next

November 12, 2026: federal hemp total-THC standard takes effect (potential watershed for hemp-derived products); watch for any congressional delay to 2027 (Vicente LLP).
March 2027: scheduled horizon for the OLCC licensing moratorium; watch whether it is extended again (Harris Sliwoski, OLCC updates).
January 1, 2027: HB 4142 ("Ryan's Law") takes effect; HB 4040 psilocybin facilitator reciprocity begins.
BM 119 litigation: Ninth Circuit appeal of the district court ruling striking the cannabis labor-peace law; outcome affects HB 4162 (Harris Sliwoski, 2026 Forecast).
Dormant-commerce-clause challenge to cannabis residency requirements; a ruling against could open Oregon to out-of-state/MSO ownership.
Legislature next convenes: the 2027 regular (long) session, which begins in January 2027; expect a renewed hemp/omnibus effort after HB 4139's failure.
Psilocybin program solvency: watch OPS fee/funding decisions and further service-center closures.

Regulators

Oregon Liquor and Cannabis Commission (OLCC): adult-use and (since 2021) most hemp-derived cannabinoid retail products (OLCC marijuana licensing).
Oregon Health Authority (OHA): medical marijuana program and Oregon Psilocybin Services (Measure 109) (OHA Psilocybin Services).
Oregon Department of Agriculture (ODA): industrial hemp grower/handler licensing and inspection.
Oregon Legislative Assembly and Governor's office: statutory policy.

Federal exposure (2026)

Oregon sits at the sharp end of every major 2026 federal drug-policy lever, and in one area (psilocybin) it is more exposed than any other state because it operates the only live program of its kind.

Rescheduling and 280E. Cannabis remains Schedule I by default. The DOJ/DEA order signed April 22, 2026 and effective April 28, 2026 (91 FR 22714) moved only FDA-approved cannabis drugs and state-licensed medical cannabis to Schedule III; recreational cannabis stays Schedule I. The order ends Section 280E (the IRS rule barring ordinary business deductions for sellers of Schedule I/II drugs) for the medical category only. Oregon's market is overwhelmingly adult-use under OLCC, so the bulk of Oregon's roughly 3,000 licensees see no 280E relief from this order; only OHA-administered medical cannabis activity falls in the relieved category, and even there the practical benefit is limited because Oregon's medical program is small relative to the adult-use market. Schedule III does not legalize cannabis, does not authorize interstate commerce, and does not reach state recreational businesses, so it changes none of Oregon's core licensing, banking, or oversupply problems. The broader DEA rescheduling hearing opened June 29, 2026 and may slip to 2027; any outcome there would still not, by itself, legalize adult-use or open interstate sales.

The November 12, 2026 hemp cliff. The FY2026 agriculture appropriations rider (Sec. 781, Rep. Andy Harris, R-MD) narrows the federal hemp definition to a total-THC standard (about 0.4 mg THC per container), recriminalizing roughly 90 to 95 percent of intoxicating hemp products effective November 12, 2026; the H.R. 7010 delay was not enacted, and the 2026 Farm Bill (H.R. 7567) keeps the ban. Oregon's direct retail exposure is lower than in permissive states because Oregon already bans artificially derived cannabinoids (delta-8, delta-10, HHC, THC-O, THC-P) under HB 3000 (2021) and HB 3825 (2025) and routes hemp-derived THC into the OLCC channel. The practical effects in Oregon are therefore felt less at the consumer shelf and more in three places: (1) Oregon hemp growers and handlers licensed through ODA who supply the national consumable-hemp market lose most of that market, on top of an already depressed hemp economy; (2) the state's stalled effort to formally align statute with the new federal standard (the collapsed omnibus HB 4139, which would have taxed hemp-derived cannabinoid products at 17 percent) leaves Oregon law lagging the federal cutover, likely forcing the 2027 long session or interim rulemaking to catch up; and (3) any compliant low-THC hemp niche that survives is the kind of narrow, capital-and-lab-intensive lane that favors larger operators. The earlier reported one-year delay to November 12, 2027 (an amendment attributed to Rep. James Comer, R-KY, unconfirmed as enacted) did not become law as of this writing (Cannabis Business Times).

Banking. SAFER Banking remains stalled in Congress, so Oregon cannabis businesses stay largely cash-reliant, locked out of mainstream banking, card networks, and ordinary lending. This compounds two state-specific pressures: the OLCC license moratorium (extended to at least March 2027) turns licenses into scarce tradable assets, and chronic oversupply has pushed wholesale prices to the floor (median usable price near $3.33/gram in April 2025). Cash-only operation plus no 280E relief for adult-use plus no new licenses plus rock-bottom prices is a combination that small, undercapitalized operators struggle to survive, while better-financed players can absorb it, an enclosure dynamic that federal inaction reinforces.

Psychedelics (the central tension). Psilocybin, MDMA, and ibogaine all remain Schedule I federally. Oregon runs the first regulated psilocybin services program in the country (Measure 109, via Oregon Psilocybin Services within OHA), so federal Schedule I creates direct, ongoing state-federal tension: the entire supply chain (manufacturers, service centers, facilitators) operates in violation of the federal Controlled Substances Act, which keeps the program cash-based, blocks banking and interstate movement of product, deters institutional capital, and exposes participants to federal enforcement risk even while they comply fully with Oregon law. The April 18, 2026 executive order, Accelerating Medical Treatments for Serious Mental Illness [https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/] plus FDA priority vouchers fast-track FDA review of psychedelic therapies, but there is no FDA approval yet. Crucially, FDA approval would not resolve Oregon's tension and could cut against the Measure 109 model: an FDA-approved psilocybin drug would most plausibly arrive as a prescription, medicalized, clinic-and-pharmacy product (and, if rescheduled, likely to Schedule III as a specific approved drug), which is a different model from Oregon's non-medical, no-diagnosis, facilitator-supervised services program. FDA approval would legitimize psilocybin-as-medicine nationally without legalizing Oregon's adult-services framework, and the medicalize-and-control federal posture would tend to favor pharmaceutical incumbents over Oregon's existing service centers. What FDA approval would change for Oregon: it could ease research, reduce stigma, and possibly create reciprocity pressure; what it would not change: the Schedule I status of the bulk-psilocybin supply chain feeding Measure 109 service centers, the banking lockout, or the program's underlying solvency problems (OHA tapped about $3.1 million from the general fund as fee revenue lagged and service centers closed).

Harm reduction. Oregon decriminalized personal possession under Measure 110 (2020) but rolled it back via HB 4002, recriminalizing simple possession effective September 1, 2024, while preserving much of the treatment funding and adding deflection off-ramps. On the federal side, SAMHSA guidance (April 24, 2026) bars federal funds for fentanyl test strips, clean syringes, and sterile water, while still supporting naloxone. This exposes Oregon's robust harm-reduction infrastructure (statewide syringe services programs, broad naloxone access, and the fentanyl-test-strip decriminalization in the 2023 HB 2395 package) to a funding squeeze: the state legalized test strips and syringe distribution, but federal dollars can no longer pay for those specific supplies, forcing Oregon to backfill with state or local funds or scale back. Naloxone programs remain federally fundable. Separately, the HALT Fentanyl Act (July 17, 2025) permanently placed fentanyl-related substances in Schedule I, a national posture that aligns with, and adds enforcement weight behind, Oregon's own recriminalization turn.

Patient access and rights

This section covers what Oregon law does and does not protect for a medical cannabis patient: use inside a hospital, and the broader rights that follow a patient into work, housing, parenting, an organ transplant list, and school. It is information, not legal advice, and it reflects the law as of July 2026. Each point links to the primary statute.

Hospital access (Ryan's Law): Oregon enacted a Ryan's Law protection in 2026. House Bill 4142, signed by Governor Kotek, allows medical cannabis use in a health care setting within a hospice and palliative-care framework, and facility rules apply. Seven states have now enacted a Ryan's Law protection (California in 2021, and Colorado, Delaware, Louisiana, Oregon, Virginia, and Washington in 2026), with Pennsylvania's bill pending.

Broader protections: Oregon's are limited. It protects housing: under Oregon Revised Statutes Section 90.303, in the landlord-tenant law, a landlord may not refuse an applicant solely for being a medical cannabis patient. But Oregon does not protect employment; Section 475C.780 declines to require an employer to accommodate medical use. A review of the cannabis chapter found no protection for a custody dispute, an organ transplant list, or school enrollment, and its general provisions offer only an immunity or defense, not a guarantee of care.

Out-of-state patients: Oregon offers no medical reciprocity; adults 21 and over use the adult-use market.

The federal picture: the April 2026 federal move of state-licensed medical cannabis to Schedule III did not change any of this. Schedule III does not make dispensary cannabis a lawful prescription medicine, and it creates no hospital-use right or employment, housing, custody, transplant, or school protection; the protections and limits above are creatures of Oregon law, not federal law.

Sources: Oregon's Ryan's Law, House Bill 4142 (2026); the housing protection, Oregon Revised Statutes Section 90.303; the employment provision, Section 475C.780.

Analysis: the enclosure read in depth

Who is fenced out and who consolidates. Oregon is a genuinely mixed case, which is why it scores in the middle rather than the high end. The open features are real and structurally important: low excise taxes by national standards (17 percent state, up to 3 percent local, no general sales tax), generous home-grow rights (4 plants per household for adults 21+), a strong and frequently used citizen-initiative tradition, and a historic in-state residency/ownership requirement that has kept multistate operators from dominating the way they do in limited-license states. Home grow in particular is a durable commons feature: it gives ordinary Oregonians a lawful supply path that no license cap or capital requirement can close, which meaningfully blunts pure enclosure.

Against that, the fencing pressures are concentrated and intensifying. The OLCC license moratorium (ratified 2024, extended to at least March 2027) operates as a near-permanent population-ratio cap with only a limited buy/sell path, which fences out new entrants entirely and converts existing licenses into scarce tradable assets that reward incumbents and the well-capitalized. Chronic oversupply and floor-level wholesale prices squeeze small producers regardless of policy. The residency wall, the main thing holding back MSO consolidation, is under direct dormant-commerce-clause attack; if it falls, out-of-state capital can buy into a capped, license-as-asset market, which is a classic consolidation setup. The Measure 110 reversal (HB 4002) re-fenced personal possession after a brief decriminalization window, with documented disproportionate-impact concerns for Black and Latino Oregonians.

State-plus-federal interaction, especially psychedelics. The federal layer mostly deepens the existing state-level enclosure rather than offsetting it. No 280E relief for adult-use, a continued banking lockout, and the November 12, 2026 hemp cliff all push toward the same outcome: small and undercapitalized actors absorb the costs and exit, while larger operators endure. Psychedelics are where state and federal logics collide most directly. Oregon built a citizen-initiated, non-medical access commons (anyone over 21 can access services without a diagnosis), but federal Schedule I keeps that commons cash-based, capital-starved, and legally precarious, and the FDA pathway, if it produces an approval, points toward a medicalized, prescription, incumbent-favoring model that would legitimize the molecule without legitimizing Oregon's open-access structure. That is enclosure by a different route: federal medicalization could hollow out the commons model even as it advances psilocybin nationally.

What to watch. Whether the OLCC moratorium is extended again past March 2027; the dormant-commerce-clause ruling on residency (a loss opens Oregon to MSO entry into a capped market); whether the 2027 long session or interim rulemaking aligns Oregon hemp statute with the federal cliff and at what tax/structure; FDA psychedelic-approval progress and whether any approval pressures or bypasses the Measure 109 model; OPS fee/funding decisions and further service-center closures; and whether Oregon backfills the SAMHSA-cut harm-reduction supplies with state funds.

Where commons counter-moves are present. Oregon retains more genuine commons features than most states: home grow as a guaranteed lawful supply path that caps cannot close; one of the country's strongest citizen-initiative traditions (Measures 67, 91, 109, and 110 were all citizen-driven), which keeps a live channel for the public to expand access over legislative resistance; and the Measure 109 psilocybin services program itself, which, financial strain notwithstanding, remains a non-medical public-access model with no analogue elsewhere. These are real counterweights to enclosure, not cosmetic ones.

Justifying the score. The score stays at 3/5. It is not lower because the fencing is concrete and compounding: a multi-year license cap that creates license-as-asset dynamics, a residency wall under live legal threat, recriminalized possession, and a federal stack (no adult-use 280E relief, banking lockout, hemp cliff, harm-reduction defunding) that all push toward consolidation and exit for small actors. It is not higher because Oregon's commons features are unusually robust and load-bearing: home grow, direct democracy, low taxes, and the open-access psilocybin model keep meaningful parts of the system open to ordinary people in ways that capped, MSO-dominated, high-tax states do not. A move to 4/5 would be warranted if the residency wall falls and MSOs consolidate the capped market, or if the psilocybin program collapses or is fully medicalized; a move to 2/5 would require the moratorium to lift, possession to be re-decriminalized, or a new citizen initiative to expand access.

Active legislation (2026)

Oregon's 2026 regular session was a 35-day short session (February 2 to March 6, 2026). The cannabis/psychedelics/drug-policy items below are the significant ones; this list is not exhaustive. For the full set and live status, use the official tracker and trade press below.

Bill	Title/Topic	Chamber	Status	Sponsor(s)
HB 4139	Omnibus cannabis/hemp bill; would tax hemp-derived cannabinoid products at 17%, add OLCC/ODA inspection and suspension powers, align with new federal hemp rules	House	Failed/stalled; referred to Ways and Means February 16, never advanced; pushed to interim working group	Unconfirmed (introduced as committee/omnibus measure; sponsor not confirmed)
HB 4142	"Ryan's Law"; expands medical-use "debilitating condition" to include hospice/palliative/comfort care, requires designated care facilities to allow on-site medical cannabis use, nurse and facility protections	House	Passed (House 39-3, Senate 20-8); signed by Governor Kotek; effective January 1, 2027	Unconfirmed (sponsor names not confirmed)
HB 4162	Effort to repeal Ballot Measure 119 (cannabis labor-peace agreements), brought amid litigation striking BM 119	House	Introduced; outcome unconfirmed	Brought at the behest of UFCW Local 555 (specific legislative sponsor unconfirmed)
SB 1548	Public health/prevention; edible individual-packaging and 10 mg per-edible cap, expanded local buffer zones beyond 1,000 feet	Senate	Failed (SB 1548A)	Brought by the Chair of the Senate Behavioral Health Committee (name unconfirmed)
HB 4040	Health omnibus incl. psilocybin facilitator reciprocity (effective Jan 1, 2027) and added dual-licensure boards	House	Passed; signed by Governor Kotek April 7, 2026 (emergency clause)	Unconfirmed

Live trackers: Oregon Legislative Information System (OLIS) 2026 measures, the Oregon State Legislature site, Marijuana Moment bill tracker, and LegiScan Oregon.

Support this work

This work is free and reader-funded. No paywalls, no ads. This brief is independent and fully sourced, and reader contributions are what keep the 50-state coverage current and answerable to readers, not advertisers or owners.

If it helped you, please chip in $5 to keep it going. Recurring support helps most; about $25 funds a full refresh of a state brief like this one.

Contribute $5 on Ko-fi Become a member

← Back to all 50 states and federal briefs

A planning snapshot for 2026, not legal advice. Policy moves quickly; confirm any single detail against the cited sources before acting on it. Sponsor names are given where confirmable and marked unconfirmed otherwise.

About the author. Jessica Mantonya is the founder of Drug Policy Watch and Hold in Common. She also advises operators, advocates, and funders on regulatory strategy and anti-enclosure positioning. Work with her →